R&D

Generic Pharmaceuticals

Development goal: 15 generics a year

Rather than continuing to develop just a few generic pharmaceuticals a year, we are strengthening our R&D capabilities-in terms of personnel and research equipment-so that we might develop more than 15 generics a year.

With 225 items, Chemiphar boasts one of the largest line-ups of generic products (as of March 2018) of any Japanese innovative drug manufacturer.

Focusing on pharmaceuticals with expired patents and the biggest market share, Chemiphar has been involved in the development of such generics as the following :

Amlodipine tablet

Amlodipine tablet
(for hypertension)

Voglibose OD tablet

Voglibose OD tablet
(for diabetes)

Rabeprazole sodium tablet

Rabeprazole sodium tablet
(proton pump inhibitors)

Donepezil hydrohloride tablet

Donepezil hydrohloride tablet
(for dementia of the Alzheimer's type)


Related Information
PageTop